US PTO grants new allowances to intellectual property covering Neurologix' GAD based delivery systems

Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, announced that the U.S. Patent and Trademark Office (US PTO) has expanded the intellectual property protections enabled by a previously issued patent that is central to Neurologix’s Parkinson’s disease program. The new allowances to U.S. Patent Number 765,446, entitled “Glutamic acid decarboxylase (GAD) based delivery systems,” broaden the patent’s coverage beyond Parkinson’s disease to include the use of GAD65 in the treatment of other neurological and related disorders.

“The covered technology is not only at the core of our Parkinson’s disease program, of which Phase 2 initial efficacy results are expected to be announced in mid-2010, but has potential application to other important diseases within our company’s core therapeutic focus.”

“This broadened coverage for Neurologix’s intellectual property in the field of gene-based medicine for brain and CNS diseases further reinforces our leadership position as an innovator in this emerging therapeutic modality,” said John Mordock, Neurologix President and Chief Executive Officer. “The covered technology is not only at the core of our Parkinson’s disease program, of which Phase 2 initial efficacy results are expected to be announced in mid-2010, but has potential application to other important diseases within our company’s core therapeutic focus.”

Source:

Neurologix, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
COVID-19 ICU patients found to have higher burden of delirium and coma